Table 3.
Cost-effectiveness results for DTG in TN and TE Patients
| Treatment | DTG | Comparator | Difference | ICER | |
|---|---|---|---|---|---|
| TN model | |||||
| EFV (Atripla®) | Cost (Can$ 2013) | 315,086 | 322,821 | −7735 | |
| LY | 27.60 | 27.13 | 0.47 | ||
| QALY | 10.620 | 10.487 | 0.132 | Dominant | |
| RAL | Cost (Can$ 2013) | 312,943 | 341,516 | −28,572 | |
| LY | 27.56 | 27.39 | 0.17 | ||
| QALY | 10.593 | 10.552 | 0.041 | Dominant | |
| DRV/r | Cost (Can$ 2013) | 312,128 | 331,221 | −19,093 | |
| LY | 27.59 | 27.38 | 0.22 | ||
| QALY | 10.607 | 10.537 | 0.070 | Dominant | |
| RPV (Complera®) | Cost (Can$ 2013) | 315,086 | 316,479 | −1393 | |
| LY | 27.60 | 27.18 | 0.42 | ||
| QALY | 10.620 | 10.506 | 0.114 | Dominant | |
| EVG (Stribild®) | Cost (Can$ 2013) | 312,943 | 323,918 | −10,975 | |
| LY | 27.56 | 27.28 | 0.28 | ||
| QALY | 10.593 | 10.515 | 0.078 | Dominant | |
| ATV/r | Cost (Can$ 2013) | 312,128 | 334,860 | −22,732 | |
| LY | 27.59 | 27.29 | 0.30 | ||
| QALY | 10.607 | 10.508 | 0.100 | Dominant | |
| LPV/r | Cost (Can$ 2013) | 312,128 | 330,877 | −18,750 | |
| LY | 27.59 | 27.22 | 0.38 | ||
| QALY | 10.607 | 10.492 | 0.116 | Dominant | |
| TE model | |||||
| RAL | Cost (Can$ 2013) | 353,957 | 357,702 | −3745 | |
| LY | 19.57 | 18.97 | 0.60 | ||
| QALY | 8.255 | 8.033 | 0.222 | Dominant | |
ATV/r ritonavir-boosted atazanavir, DRV/r ritonavir-boosted darunavir, DTG dolutegravir, EFV efavirenz, EVG elvitegravir, ICER incremental cost-effectiveness ratio, LPV/r ritonavir-boosted lopinavir, LY life-year, QALY quality-adjusted life-year, RAL raltegravir, RPV rilpivirine, TE treatment-experienced, TN treatment-naive